Detalhe da pesquisa
1.
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
Mult Scler
; 28(6): 910-924, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34605319
2.
Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in the Russian Population.
J Int Neuropsychol Soc
; 28(5): 503-510, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34132190
3.
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.
Neurol Ther
; 11(2): 741-758, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35284994
4.
Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.
PLoS One
; 14(5): e0217303, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31136608
5.
Drug Policy in the Russian Federation.
Value Health Reg Issues
; 16: 106-111, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30327255
6.
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.
Neurol Ther
; 11(2): 759-762, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35503396